Biological Products, (No Diagnostic Substances)
Standard Industrial Classification: SIC 2836
Industry Insider Sentiment Analysis
The Biological Products, (No Diagnostic Substances) sector (SIC 2836) acts as a critical barometer for broader economic health. Our real-time monitoring reveals 15759 total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-18 03:47 | 2026-02-17 | AURA | Aura Biosciences, Inc. | Hopkins Janet Jill | Officer | SELL | $5.06 | 20,401 | $103,229 | 232,284 |
| 2026-02-18 03:47 | 2026-02-17 | AURA | Aura Biosciences, Inc. | Elazzouzi Amy | Officer | SELL | $5.06 | 8,549 | $43,258 | 75,532 |
| 2026-02-18 03:46 | 2026-02-17 | AURA | Aura Biosciences, Inc. | de los Pinos Elisabet | Director, Officer | SELL | $5.06 | 47,648 | $241,099 | 409,815 |
| 2026-02-18 03:15 | 2026-02-17 | TNYA | Tenaya Therapeutics, Inc. | Higa Tomohiro | Officer | SELL | $0.64 | 3,469 | $2,231 | 119,752 |
| 2026-02-18 03:14 | 2026-02-17 | TNYA | Tenaya Therapeutics, Inc. | Ali Faraz | Director, Officer | SELL | $0.64 | 14,862 | $9,556 | 443,404 |
| 2026-02-18 03:13 | 2026-02-17 | TNYA | Tenaya Therapeutics, Inc. | Tingley Whittemore | Officer | SELL | $0.64 | 5,160 | $3,319 | 218,618 |
| 2026-02-18 00:25 | 2026-02-12 | TWST | Twist Bioscience Corp | Finn Patrick John | Officer | OPT+S | $50.16 | 5,250 | $263,359 | 306,250 |
| 2026-02-17 16:30 | 2026-02-12 | ENTX | Entera Bio Ltd. | Rubin Steven D | Director | BUY | $1.49 | 5,000 | $7,450 | 15,000 |
| 2026-02-17 14:22 | 2026-02-12 | ZIVO | Zivo Bioscience, Inc. | STROME MARK E | 10% owner | BUY | $9.77 | 20,000 | $195,400 | 472,942 |
| 2026-02-14 04:10 | 2026-02-12 | PALI | PALISADE BIO, INC. | Jones Mitchell Lawrence | Officer | OPT+S | $1.75 | 1,989 | $3,481 | 13,263 |
| 2026-02-14 04:07 | 2026-02-12 | PALI | PALISADE BIO, INC. | Finley John David | Director, Officer | OPT+S | $1.75 | 3,896 | $6,818 | 27,353 |
| 2026-02-14 04:00 | 2026-02-11 | APGE | Apogee Therapeutics, Inc. | HENDERSON MICHAEL THOMAS | Director, Officer | SELL | $63.35 | 20,000 | $1,266,952 | 1,172,987 |
| 2026-02-14 01:10 | 2026-02-12 | TWST | Twist Bioscience Corp | Laponis Adam | Officer | SELL | $50.00 | 7,000 | $350,000 | 130,031 |
| 2026-02-14 01:00 | 2026-02-12 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Officer | SELL | $12.03 | 416 | $5,004 | 128,219 |
| 2026-02-14 00:19 | 2026-02-11 | SRZN | Surrozen, Inc./DE | TCG Crossover GP II, LLC | 10% owner | BUY | $23.59 | 18,856 | $444,845 | 651,112 |
| 2026-02-14 00:05 | 2026-02-11 | VCEL | Vericel Corp | MCLAUGHLIN KEVIN F | Director | OPT+S | $34.66 | 7,000 | $242,620 | 15,100 |
| 2026-02-14 00:05 | 2026-02-11 | TWST | Twist Bioscience Corp | Cho Dennis | Officer | SELL | $49.93 | 5,000 | $249,650 | 138,581 |
| 2026-02-13 01:19 | 2026-02-10 | TNYA | Tenaya Therapeutics, Inc. | COLUMN GROUP III GP, LP | 10% owner | SELL | $0.69 | 4,400,290 | $3,042,361 | 2,651,817 |
| 2026-02-13 00:15 | 2026-02-11 | TECX | Tectonic Therapeutic, Inc. | REICIN ALISE | Director, Officer | BUY | $21.10 | 2,500 | $52,750 | 237,547 |
| 2026-02-12 17:21 | 2026-02-10 | ZIVO | Zivo Bioscience, Inc. | YALDOO LAITH L | Director, 10% owner | BUY | $10.27 | 2,434 | $24,997 | 582,072 |
| 2026-02-12 03:08 | 2026-02-09 | KRYS | Krystal Biotech, Inc. | ROMANO KATHRYN | Officer | OPT+S | $272.14 | 12,500 | $3,401,705 | 19,318 |
| 2026-02-12 01:32 | 2026-02-10 | TECX | Tectonic Therapeutic, Inc. | Lochner Daniel | Officer | BUY | $21.61 | 6,000 | $129,660 | 32,044 |
| 2026-02-12 00:32 | 2026-02-10 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | Officer | SELL | $3.85 | 4,569 | $17,591 | 210,078 |
| 2026-02-12 00:30 | 2026-02-10 | VYGR | Voyager Therapeutics, Inc. | Sandrock Alfred | Director, Officer | SELL | $3.78 | 12,192 | $46,086 | 509,989 |
| 2026-02-12 00:30 | 2026-02-10 | VYGR | Voyager Therapeutics, Inc. | Carter Todd Alfred | Officer | SELL | $3.85 | 3,525 | $13,571 | 153,193 |
| 2026-02-11 16:47 | 2026-02-10 | ENTX | Entera Bio Ltd. | Taitel Haya | Director | BUY | $1.48 | 7,500 | $11,100 | 0 |
| 2026-02-11 16:45 | 2026-02-10 | ENTX | Entera Bio Ltd. | Germano Geno J | Director | BUY | $1.49 | 20,000 | $29,800 | 0 |
| 2026-02-11 16:44 | 2026-02-09 | ENTX | Entera Bio Ltd. | Rubin Steven D | Director | BUY | $1.20 | 10,000 | $12,000 | 10,000 |
| 2026-02-11 16:42 | 2026-02-09 | ENTX | Entera Bio Ltd. | Ellis Sean | Director | BUY | $1.24 | 18,000 | $22,320 | 178,098 |
| 2026-02-11 01:05 | 2026-02-09 | BIIB | BIOGEN INC. | Singhal Priya | Officer | OPT+S | $199.83 | 2,660 | $531,548 | 8,043 |
| 2026-02-10 05:19 | 2026-02-06 | EIKN | Eikon Therapeutics, Inc. | Column Group IV GP, LP | 10% owner | BUY | $18.00 | 2,117,760 | $38,119,680 | 1,319,164 |
| 2026-02-10 00:26 | 2026-02-06 | TWST | Twist Bioscience Corp | JOHANNESSEN JAN | Director | SELL | $47.91 | 2,200 | $105,395 | 17,754 |
| 2026-02-07 03:37 | 2026-02-04 | EIKN | Eikon Therapeutics, Inc. | Foresite Capital Management IV, LLC | 10% owner | BUY | $18.00 | 55,555 | $999,990 | 1,318,983 |
| 2026-02-07 03:30 | 2026-02-04 | ADPT | Adaptive Biotechnologies Corp | PISKEL KYLE | Officer | OPT+S | $18.46 | 2,145 | $39,597 | 216,637 |
| 2026-02-07 02:33 | 2026-02-04 | EIKN | Eikon Therapeutics, Inc. | FRAZIER KENNETH C | Director | BUY | $18.00 | 111,111 | $1,999,998 | 111,111 |
| 2026-02-07 02:27 | 2026-02-04 | EIKN | Eikon Therapeutics, Inc. | Wolfe Josh | Director, 10% owner | BUY | $18.00 | 277,776 | $4,999,968 | 138,888 |
| 2026-02-07 02:25 | 2026-02-04 | EIKN | Eikon Therapeutics, Inc. | Lux Venture Partners V, LLC | 10% owner | BUY | $18.00 | 277,776 | $4,999,968 | 138,888 |
| 2026-02-07 02:05 | 2026-02-04 | SLDB | Solid Biosciences Inc. | Howton David T | Officer | SELL | $6.44 | 18,894 | $121,713 | 97,859 |
| 2026-02-07 02:01 | 2026-02-04 | SLDB | Solid Biosciences Inc. | Cumbo Alexander | Director, Officer | SELL | $6.44 | 48,913 | $315,093 | 222,018 |
| 2026-02-07 02:01 | 2026-02-04 | SLDB | Solid Biosciences Inc. | Ganot Ilan | Director | SELL | $6.44 | 7,205 | $46,414 | 25,271 |
| 2026-02-07 02:00 | 2026-02-04 | SLDB | Solid Biosciences Inc. | Tan Kevin | Officer | SELL | $6.44 | 14,783 | $95,231 | 94,201 |
| 2026-02-07 01:59 | 2026-02-04 | SLDB | Solid Biosciences Inc. | Brooks Gabriel | Officer | SELL | $6.44 | 12,616 | $81,271 | 84,092 |
| 2026-02-07 01:57 | 2026-02-04 | SLDB | Solid Biosciences Inc. | Hanrahan Jessie | Officer | SELL | $6.44 | 12,348 | $79,545 | 70,327 |
| 2026-02-07 01:56 | 2026-02-04 | SLDB | Solid Biosciences Inc. | Herzich Paul | Officer | SELL | $6.44 | 10,905 | $70,249 | 69,067 |
| 2026-02-07 01:53 | 2026-02-04 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Director | SELL | $4.12 | 40,000 | $164,800 | 913,839 |
| 2026-02-07 01:53 | 2026-02-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Borgeson Blake | Director | SELL | $4.20 | 220,000 | $924,000 | 6,429,863 |
| 2026-02-07 00:30 | 2026-02-04 | TSHA | Taysha Gene Therapies, Inc. | Alam Kamran | Officer | SELL | $4.52 | 1,655 | $7,481 | 1,442,131 |
| 2026-02-07 00:22 | 2026-02-05 | GILD | GILEAD SCIENCES, INC. | O'Day Daniel Patrick | Director, Officer | OPT+S | $150.00 | 115,640 | $17,346,000 | 613,912 |
| 2026-02-06 03:38 | 2026-02-03 | HALO | HALOZYME THERAPEUTICS, INC. | Torley Helen | Director, Officer | OPT+S | $77.07 | 50,000 | $3,853,505 | 708,719 |
| 2026-02-06 00:14 | 2026-02-03 | IPSC | Century Therapeutics, Inc. | Carr Douglas | Officer | SELL | $1.82 | 323 | $589 | 514,551 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Biological Products, (No Diagnostic Substances) sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2836) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Biological Products, (No Diagnostic Substances)
Every transaction in the Biological Products, (No Diagnostic Substances) industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.